Through Thick and Thin.

Slides:

Advertisements

Similar presentations

B - body M - mass I - index. The body mass index (BMI), or Quetelet index, is a measure for human body shape based on an individual's weight and height.

Advertisements

Understanding Your Fitness

Source: Behavioral Risk Factor Surveillance System, CDC. Obesity Trends* Among U.S. Adults BRFSS, 1985 No Data

Smoking Cessation in Smokers Motivated to Quit Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Robert Anthenelli.

Calculating Body Mass Index (BMI) Body Mass Index (BMI) is used to assess a persons body weight. The number given allows you to see if you are underweight,

A Randomised Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients with or without Comorbidities A Randomised Double-Blind.

Body Mass Index (BMI) This is the most commonly used index of over or underweight Body Mass Index = body weight ( Height) squared ClassificationBMI.

WHAT IS BMI? BMI BODY MASS INDEX- BASED ON HEIGHT AND WEIGHT TO DETERMINE AMOUNT OF FAT AN INDIVIDUAL HAS OBESE BMI > 30.

© NOO 2012 noo National Obesity Observatory Examining available data for the adult population.

Determinants of Pre-Conception Nutrition- weight Dr. Eeson Sinthamoney MD (Mal), MRCOG (London), DFFP (UK) Fellowship in Reproductive Medicine (Singapore/UK)

Management of Obesity in Diabetes Key Messages An estimated 80 to 90% of persons with type 2 diabetes are overweight or obese. A modest weight loss of.

(*BMI ≥30, or ~ 30 lbs. overweight for 5’ 4” person) No Data

How to Calculate Your Body Mass Index (BMI)

Monitoring Tracings US (bpm) LV FHR (bpm) Pulse ox LV MHR (bpm) VS.

Addressing the Challenges in Primary and Secondary Stroke Prevention

Weightproblems by teenagers

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal Gregory.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

US Guidelines US Guidelines Low-risk Patients.

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

The ABCs of AF.

NOACs in Clinical Practice: Are They All the Same?

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

A New Era for NOACs:.

Achieving and Maintaining Weight Loss in Obesity: Clinical Evidence for Novel Approaches.

Up to Date on Which NOAC for Which Patient

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

The Essentials for Secondary Stroke Prevention

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

New Oral Anticoagulants and VTE Management

VTE Treatment Conventional Approach

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

NOACS: Emerging data in ACS/IHD

Efficacy and Safety of Edoxaban in Patients With AF and HF

A Better Solution For Cancer Patients With VTE?

Oral Anticoagulation in AF

Dos and Don’ts for High-Risk Elderly Patients With AF

Atrial Fibrillation.

Extraordinary Cases of VTE Prevention in Patients With Cancer

M. Kats, A.M. Hawxby, J. Barker, M. Allon Kidney International

Advances in Peanut Allergy

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

A Time for Change for Managing Patients With VTE Who Have Cancer

What You Didn't Know About AF and Renal Dysfunction

A Case Challenge.

New European Anticoagulant Approvals Will They Affect Practical Guidance?

Obesity and Alcohol Synergize to Increase the Risk of Incident Hepatocellular Carcinoma in Men Rohit Loomba, Hwai-I. Yang, Jun Su, David Brenner, Uchenna.

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Supplemental Table 1: Differences in mean BMI-SDS between 2005 and 2015 – the obese lose weight while the overweight stabilize or even increase weight.

NOAC Studies in VTE AF Studies Superior Outcomes.

Reducing Risk for CV Outcomes

M. Kats, A.M. Hawxby, J. Barker, M. Allon Kidney International

The ABCs of AF.

Disease Burden of VTE Phases of VTE Treatment.

5 Good Minutes on Atrial Fibrillation-related Stroke

Antiarrhythmic Drugs in AF

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Through Thick and Thin

Program Goal

AF and Weight

Facts About Overweight and Obesity

Weight as a Risk Factor for AF

Distribution of BMI (kg/m2) in ENGAGE-AF

Efficacy and Safety by BMI Category

Case Patient With Obesity

Clinical Implications of NOAC Dosing in Extremes of Weight

Weight Extremes for NOACs

Concerns About Dosing in Underweight Patients

Edoxaban in Patients at Risk of Falling

"Risk for Falls" in ENGAGE-AF

Patients With an Increased Risk for Falls Select Efficacy and Safety Endpoints

Absolute Risk Reduction of Edoxaban vs Warfarin in Patients at Risk of Falling

Dose Reduction in NOAC Trials

NOAC Dosing Recommendations for Body Weight Extremes

Take-Home Messages